News & Updates
Filter by Specialty:
Does CKD reduce tirzepatide benefits on HFpEF patients with obesity?
Long-term treatment with tirzepatide results in improved renal function in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, regardless of the absence or presence of chronic kidney disease (CKD), according to a post hoc analysis of the SUMMIT trial presented at ACC.25.
Does CKD reduce tirzepatide benefits on HFpEF patients with obesity?
15 Apr 2025
TB vax primer augments BCG-induced immune response in bladder cancer patients
Initial results of the phase I RUTIVAC-1 study show the potential of two doses of a tuberculosis (TB) vaccine given after surgery but before standard BCG* treatment to boost immunity and reduce the odds of recurrence in patients with non-muscle-invasive bladder cancer (NMIBC).
TB vax primer augments BCG-induced immune response in bladder cancer patients
15 Apr 2025
Shockwave therapy plus tadalafil beneficial to Asians with ED
In the treatment of mild to moderate erectile dysfunction (ED), low-intensity extracorporeal shockwave therapy combined with tadalafil helps improve outcomes, according to the preliminary results of a study from China.
Shockwave therapy plus tadalafil beneficial to Asians with ED
14 Apr 2025
Stepwise DAPT de-escalation on par with standard therapy in ACS
A stepwise dual antiplatelet therapy (DAPT) de-escalation strategy among patients with acute coronary syndrome (ACS) who could be treated by paclitaxel-coated balloons without stents demonstrates noninferiority to the standard 12-month DAPT for all net adverse clinical events, according to a study.
